![[8]-Shogaol](https://file.medchemexpress.com/product_pic/hy-n2435.gif "Click to View [8]-Shogaol Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
72 Results for "
synovial
" in MedChemExpress (MCE) Product Catalog:
Products (72)
72 Results for "synovial" in MCE Product Catalog:
17
Category:
Infection Natural Products Microorganisms Disease Research Fields Inflammation/Immunology Cancer
Target:
13
13
13 Cited Publications
Synonyms: D-(+)-Glucosamine hydrochloride; Chitosamine hydrochloride
13
10
Target:
Research Areas:
Alizarin Red S sodium is an anthraquinone derivative dye. When combined with cations such as calcium ions, the functional group of Alizarin Red S sodium can form a coordination bond with the cation through the oxygen atom to show orange-red fluorescence. Alizarin Red S sodium can be used for screening of calcium compounds in synovial fluid and detecting osteoblast differentiation, and can also be used for bone staining in mice. Excitation/emission wavelength: 500/570 nm .
10
Target:
Research Areas:
Alizarin Red S (ARS) is an anthraquinone derivative dye. When combined with cations such as calcium ions, the functional group of Alizarin Red S can form a coordination bond with the cation through the oxygen atom to show orange-red fluorescence. Alizarin Red S can be used for screening of calcium compounds in synovial fluid and detecting osteoblast differentiation, and can also be used for bone staining in mice. Excitation/emission wavelength: 500/570 nm .
4
4
4 Cited Publications
Cat. No.: HY-N2435
CAS No.: 36700-45-5
3
3 Cited Publications
Research Areas:
FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD, Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma .
3
3 Cited Publications
Target:
Research Areas:
CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma .
1
Collagenase, Type VI (EC 3.4.24.3) is a collagenase that can degrade type VI collagen. Type VI collagen is a component of cell membranes in various tissues (such as skin, heart, blood vessels, cartilage, and synovial fluid). Excessive collagenase can cause extracellular matrix lesions. Collagenase is also a biomarker for tumor invasion and metastasis. Collagenase, Type VI can specifically act on the peptide bond between proline and glycine. This feature can be used to quickly and sensitively detect its concentration level in experiments using corresponding modified electrodes .
Cat. No.: HY-B0808
CAS No.: 21256-18-8
Synonyms: Oxaprozinum; Wy21743
Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties .
Cat. No.: HY-P99781
CAS No.: 1610761-46-0
Synonyms: MLN-1202
Target:
Research Areas:
Cat. No.: HY-159579
CAS No.: 3055592-99-6
Target:
Research Areas:
CW-3308 is an orally active BRD9 PROTAC degrader with an DC50 of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .
Synonyms: NI-0101
Target:
Research Areas:
Paridiprubart (WT IgG1) (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart (WT IgG1) inhibits the production of pro-inflammatory cytokines by monocytes from rheumatoid arthritis specimen induced by rheumatoid arthritis synovial fluid (RASF). Paridiprubart (WT IgG1) can be used for the study of rheumatoid arthritis .
Cat. No.: HY-148739
CAS No.: 2170679-42-0
Target:
Research Areas:
dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
Cat. No.: HY-160822
CAS No.: 920289-29-8
Synonyms: PF-5212371
Research Areas:
AGG-523 (PF-5212371) is an orally active, reversible, non-hydroxamate, zinc-binding selective inhibitor of ADAMTS4 and ADAMTS5 with IC50 of <0.03 and 0.04 μM. AGG-523 also inhibits MMP-2, -8, 12 activity AGG-523 attenuates release of aggrecanase-generated ARG-aggrecan fragments into synovial fluid, reduces surgery-induced ARG-aggrecan release in rat joint models, and inhibits aggrecanase activity to slow cartilage degradation. AGG-523 can be used for the research of osteoarthritis .
Cat. No.: HY-N0475
CAS No.: 74285-86-2
Synonyms: Hypolide; (+)-Triptophenolide
Synonyms: ISC-27864; GRC-27864
Target:
Research Areas:
Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .
Cat. No.: HY-156744
Purity: 98.87%
Target:
Research Areas:
DBr-1 is a potent BRD9 PROTAC degrader with a DC50 of 90 nM. DBr-1 mediates the ubiquitination and proteasomal degradation of BRD9 via the ubiquitin-proteasome pathway. DBr-1 is applicable to research related to renal cell carcinoma and synovial sarcoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
